Related Experiment Videos
One year experience with a low density lipoprotein apheresis system.
Ronen Durst1, Deborah Rund, Daniel Schurr
1Department of Medicine B and Center for Research, Prevention and Treatment of Atherosclerosis, Hadassah University Hospital, Hebrew University Medical School, Jerusalem, Israel.
The Israel Medical Association Journal : IMAJ
|November 21, 2002
Summary
Low density lipoprotein (LDL) apheresis with the DALI system effectively lowers cholesterol in hypercholesterolemia patients. While generally safe and beneficial, some patients experience side effects during initial treatments.
Area of Science:
- Cardiology
- Nephrology
- Biomedical Engineering
Background:
- Low density lipoprotein (LDL) apheresis is a supplementary treatment for hypercholesterolemia unresponsive to conventional therapies.
- The DALI system is the sole extracorporeal system for LDL removal that is compatible with whole blood.
Purpose of the Study:
- To evaluate the one-year clinical experience with the DALI system for LDL apheresis.
Main Methods:
- LDL apheresis was performed on 13 patients with hypercholesterolemia, including familial hypercholesterolemia, statin intolerance, and ischemic heart disease.
- The DALI system was utilized for LDL-C reduction in all participants.
Main Results:
- Significant reductions in triglyceride, total cholesterol, and LDL-C levels were observed post-treatment.
- Adverse events, including allergic reactions, rhabdomyolysis, and myopathy, occurred in five patients, primarily during early sessions.
- HDL-C levels showed a less pronounced change compared to plasma exchange.
Conclusions:
- LDL apheresis with the DALI system demonstrates high efficacy in managing hypercholesterolemia.
- Early treatment sessions are associated with potential side effects, but the therapy is well-tolerated and clinically beneficial for patients without adverse reactions.